Pernix Therapeutics Holdings
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Pernix Therapeutics Holdings met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded significantly, and GAAP earnings per share improved significantly.
Margins improved across the board.
Pernix Therapeutics Holdings notched revenue of $21.4 million. The four analysts polled by S&P Capital IQ expected net sales of $21.2 million on the same basis. GAAP reported sales were 75% higher than the prior-year quarter's $12.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.16. The five earnings estimates compiled by S&P Capital IQ averaged $0.14 per share on the same basis. GAAP EPS of $0.15 for Q4 were 114% higher than the prior-year quarter's $0.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 100%, 3,420 basis points better than the prior-year quarter. Operating margin was 28.1%, 410 basis points better than the prior-year quarter. Net margin was 18.1%, 590 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $15.4 million. On the bottom line, the average EPS estimate is $0.07.
Next year's average estimate for revenue is $84.9 million. The average EPS estimate is $0.44.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is buy, with an average price target of $17.83.
Over the decades, small-cap stocks like Pernix Therapeutics Holdings have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Pernix Therapeutics Holdings to My Watchlist.